Page last updated: 2024-11-08

sulfolipid i

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

sulfolipid I: principal sulfolipid class of virulent human Mycobacterium tuberculosis strain H(37)Rv [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfolipid I : The principal sulfolipid class of virulent human Mycobacterium tuberculosis strain H(37)Rv. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID46878365
CHEBI ID26828
MeSH IDM0053981

Synonyms (4)

Synonym
sulfolipid i
6-o-[(2s,4s,6s,8s,10r,12r,14r,16r,17r)-17-hydroxy-2,4,6,8,10,12,14,16-octamethyldotriacontanoyl]-2-o-sulfo-alpha-d-glucopyranosyl 3-o-[(2s,4s,6s,8s,10r,12r,14r,16r,17r)-17-hydroxy-2,4,6,8,10,12,14,16-octamethyldotriacontanoyl]-6-o-[(2s,4s,6s,8s,10s,12s,14
2-palmitoyl-3-phthioceranoyl-6,6'-bis(hydroxyphthioceranoyl) trehalose-2'-sulfate
CHEBI:26828
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sulfoglycolipidA sulfate ester of a glycolipid.
polyacyl alpha,alpha-trehalose derivativeA glycolipid that is an alpha,alpha-trehalose derivative in which two or more of the trehalose hydroxy groups are acylated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (13.64)18.7374
1990's2 (9.09)18.2507
2000's9 (40.91)29.6817
2010's7 (31.82)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]